Microbot Medical has announced that ELMNT IR, a multisite outpatient interventional radiology practice in California, has signed an order to purchase up to a 12-month supply of the company’s Liberty endovascular robotic system.
A press release notes that ELMNT IR became the first office-based laboratory (OBL) customer in the world to utilise the Liberty system, and Microbot’s first customer on the West Coast of the USA.
Jonathan Steinberger, co-founder of ELMNT IR, has already performed multiple procedures using the Liberty system, including Y90 mapping for the treatment of liver tumours, prostate artery embolisation (PAE) for the treatment of benign prostatic hyperplasia (BPH), and genicular artery embolisation (GAE) for symptomatic knee osteoarthritis.
“Having used Liberty for multiple procedures, I’ve found that the combination of a compact footprint, efficient workflow, and the elimination of upfront capital costs and expenses associated with traditional equipment makes Liberty an optimal system for establishing an endovascular robotic programme in an OBL,” said Steinberger. “We have seen firsthand the value it can bring to physicians and patients. Based on our experience to date, Liberty is well positioned to become a standard for the use of robotics in endovascular intervention procedures.”
“This is a significant milestone for us, and we believe it supports the value that Liberty brings across multiple sites of care settings, especially in OBLs, as we believe they are an important and growing segment of the market,” commented Harel Gadot, chairman, CEO, and president of Microbot Medical. “Our relationship with ELMNT IR, which has already resulted in advance orders of the Liberty system from ELMNT IR, continues a trend in which every customer that has utilised its initial Liberty inventory has subsequently reordered additional systems. We believe this reflects high satisfaction among physicians, as well as the acceptance by hospital administration, as they recognise the value of the system. Furthermore, in addition to expanding access to healthcare networks, this represents an additional revenue opportunity for the Liberty system as we expect the number of peripheral vascular interventions performed in OBLs to continue to increase.”
Microbot shares that Liberty is the only US Food and Drug Administration (FDA)-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
